Peer-reviewed veterinary case report
Vaccine trial with H1 and HASPB1 proteins protects some dogs
By Moreno, J et al.·Published in Vaccine·2007·WHO Collaborating Centre for Leishmaniasis, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.
- Species:
- dog
Plain-English summary
Eight beagle dogs were vaccinated with different combinations of Leishmania proteins to see if they could be protected from a serious infection. After being exposed to the parasite, five of the dogs that received a vaccine with the H1 protein and Montanide remained healthy, while four out of eight dogs that got a combination of the HASPB1 protein and Montanide also showed no symptoms. In contrast, only two dogs from the control group and two that received a different vaccine remained symptom-free. This suggests that the H1 and HASPB1 proteins can help protect dogs from leishmaniasis, even in challenging conditions.
People also search for: dog leishmaniasis vaccine · beagle dog vaccine trial · canine leishmaniasis symptoms · how to protect dog from leishmaniasis
Abstract
The protective capabilities of three Leishmania recombinant proteins - histone 1 (H1) and hydrophilic acylated surface protein B1 (HASPB1) immunized singly, or together as a protein cocktail vaccine with Montanide, and the polyprotein MML immunized with MPL-SE adjuvant - were assessed in beagle dogs. Clinical examination of the dogs was carried out periodically under blinded conditions and the condition of the dogs defined as asymptomatic or symptomatic. At the end of the trial, we were able to confirm that following infection with L. infantum promastigotes, five out of eight dogs immunized with H1 Montanide, and four out of eight dogs immunized with either the combination of HASPB1 with Montanide or the combination of H1+HASPB1 with Montanidetrade mark, remained free of clinical signs, compared with two out of seven dogs immunized with the polyprotein MML and adjuvant MPL-SE, and two out of eight dogs in the control group. The results demonstrate that HASPB1 and H1 antigens in combination with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17576026/